Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

  • Technology appraisal guidance
  • TA1109
  • Published: 

History

Documents created during the development process.

Final draft guidance

Invitation to participate

Referral

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6452

Topic selection